Notably, the CY/CY +CSA treated group had significantly lower plasma albumin levels than CY/BEN +CSA (Figure 3E, P=0.0059) or untreated mice (P=0.0075), which has been identified as a potential biomarker for severe (grade 3-4) acute GvHD development in patients undergoing allo-HCT (23, 24). This evidence concerns the gene ALB and graft versus host disease.